Given the significant reduction in death and the absolute major bleeding rates, I think the 2.5mg rivaroxaban dose has a good risk/reward profile in ACS.
Karen A. Hicks, M.D., the FDA reviewer seems to agree with this. From page 16 in the briefing docs:
I recommend approval of XARELTO® (2.5 mg po BID) to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS)
Market Data 
Markets 
AI
